Lead Product(s) : VDPHL01
Therapeutic Area : Dermatology
Study Phase : Phase II/ Phase III
Sponsor : Suvretta Capital
Deal Size : $75.0 million
Deal Type : Series B Financing
Veradermics Raises $75M, Starts Phase 2/3 Hair Loss Therapy Trial
Details : The proceeds from the financing will be used to fund the ongoing pivotal clinical development of Veradermics’ lead candidate VDPHL01 for the treatment of androgenetic alopecia
Product Name : VDPHL01
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 11, 2024
Lead Product(s) : VDPHL01
Therapeutic Area : Dermatology
Highest Development Status : Phase II/ Phase III
Sponsor : Suvretta Capital
Deal Size : $75.0 million
Deal Type : Series B Financing
Lead Product(s) : Difelikefalin Acetate
Therapeutic Area : Dermatology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cara Therapeutics: Outcome of KOURAGE-1 Study on Oral Difelikefalin in Notalgia
Details : Korsuva (difelikefalin) is a kappa opioid receptor agonists. Its oral formulation is under development for the treatment of moderate-to-severe pruritus in adult patients with notalgia paresthetica.
Product Name : Korsuva
Product Type : Peptide
Upfront Cash : Inapplicable
December 06, 2024
Lead Product(s) : Difelikefalin Acetate
Therapeutic Area : Dermatology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Izokibep
Therapeutic Area : Dermatology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IMG-020 (izokibep) is a small therapeutic protein inhibitor of interleukin-17A (IL-17A). It is designed to overcome monoclonal antibodies limitations for hidradenitis suppurativa indication. It is being investigated for moderate-to-severe Hidradenitis.
Product Name : ABY-035
Product Type : Protein
Upfront Cash : Inapplicable
November 09, 2023
Lead Product(s) : Izokibep
Therapeutic Area : Dermatology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Izokibep
Therapeutic Area : Dermatology
Study Phase : Phase II/ Phase III
Sponsor : Morgan Stanley
Deal Size : $621.0 million
Deal Type : Public Offering
Details : Company will use the proceeds to fund its operations, including the development of pipeline including Izokibep and commercialization activities, business development activities, and capital expenditures.
Product Name : ABY-035
Product Type : Protein
Upfront Cash : Undisclosed
September 05, 2023
Lead Product(s) : Izokibep
Therapeutic Area : Dermatology
Highest Development Status : Phase II/ Phase III
Sponsor : Morgan Stanley
Deal Size : $621.0 million
Deal Type : Public Offering
Lead Product(s) : B244
Therapeutic Area : Dermatology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AOBiome Therapeutics Granted Composition of Matter Patent for its Clinical Candidate B244
Details : B244 platform is a patented, proprietary, topical formulation. Once deployed, B244 produces nitric oxide, a signaling molecule known to regulate inflammation and vasodilation. It has shown clinical significance for atopic dermatitis and associated prurit...
Product Name : B244
Product Type : Microorganism
Upfront Cash : Inapplicable
June 04, 2023
Lead Product(s) : B244
Therapeutic Area : Dermatology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Izokibep
Therapeutic Area : Dermatology
Study Phase : Phase II/ Phase III
Sponsor : Morgan Stanley
Deal Size : $540.0 million
Deal Type : Public Offering
ACELYRIN, INC. Announces Pricing of Upsized Initial Public Offering
Details : The net proceeds will be used to advance the clinical development of izokibep through topline data in Phase 2b/3 trials of izokibep in each of HS, PsA, and uveitis.
Product Name : ABY-035
Product Type : Protein
Upfront Cash : Undisclosed
April 05, 2023
Lead Product(s) : Izokibep
Therapeutic Area : Dermatology
Highest Development Status : Phase II/ Phase III
Sponsor : Morgan Stanley
Deal Size : $540.0 million
Deal Type : Public Offering
Lead Product(s) : Nalbuphine Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Primary efficacy endpoint demonstrated 77.3% reduction in daytime cough frequency from baseline with use of Haduvio (nalbuphine ER) compared to 25.7% reduction with placebo, 52% placebo-adjusted reduction in geometric mean percent change in daytime cough...
Product Name : Haduvio
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 24, 2022
Lead Product(s) : Nalbuphine Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nalbuphine Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Haduvio (oral nalbuphine ER) demonstrated statistically significant results on the primary efficacy endpoint as measured by a 4-point reduction in the Worst Itch – Numerical Rating Scale (WI-NRS) (p=0.0157).
Product Name : Haduvio
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 29, 2022
Lead Product(s) : Nalbuphine Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nalbuphine Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Trevi Therapeutics Completes Enrollment for Phase 2b/3 PRISM Study in Chronic Pruritus in PN
Details : Phase 2b/3 PRISM trial enrollment completed for Haduvio (nalbuphine ER), mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist for the treatment of pruritus associated with prurigo nodularis.
Product Name : Haduvio
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 02, 2022
Lead Product(s) : Nalbuphine Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nalbuphine Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Phase II/ Phase III
Sponsor : Stifel
Deal Size : $11.8 million
Deal Type : Private Placement
Trevi Therapeutics Announces $11.8 Million Private Placement Priced At-the-Market
Details : The Company will use the net proceeds from the private placement for the development of an investigational therapy Haduvio™, an oral extended-release (ER) formulation of nalbuphine to treat serious neurologically mediated conditions.
Product Name : Haduvio
Product Type : Controlled Substance
Upfront Cash : Undisclosed
September 30, 2021
Lead Product(s) : Nalbuphine Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase II/ Phase III
Sponsor : Stifel
Deal Size : $11.8 million
Deal Type : Private Placement